Enlivex Reports Durable 12-Month Response With Allocetra In Knee Osteoarthritis Trial
Enlivex (ENLV) reported 12-month Phase I/IIa trial results for Allocetra, showing 79.2% of older patients with knee osteoarthritis experienced reduced pain and improved function vs. 47.6% with placebo. The therapy demonstrated a favorable safety profile. The company plans to present findings at ACR Convergence 2026 and expects Phase IIb trial data by Q2 2027. ENLV stock closed at $1.15, up 2.68%.
How this was made

The 30-second read
Why it matters
The durable 12-month responder rates and favorable safety profile can strengthen the clinical narrative for Allocetra, but the stated absence of statistical significance for some individual measures at 12 months suggests investors may wait for Phase IIb topline to confirm efficacy.
Market read
Traders may adjust probabilities for Allocetra’s Phase IIb success based on durability and safety, while monitoring whether Phase IIb endpoints achieve statistical significance.
What to watch
Responder-rate comparisons are reported for older patients, but the article does not provide full statistical details, endpoint definitions, or effect sizes for the non-significant measures, which may matter for how investors underwrite Phase IIb odds.
Background
Allocetra is an investigational cell-based therapy targeting inflammation, dosed as a single cycle of three knee injections in a Phase I/IIa design with a safety stage and randomized, double-blind placebo-controlled Phase IIa stage.
Ticker impact
Enlivex reports positive 12-month Phase I/IIa Allocetra results in knee osteoarthritis, including 79.2% pain/function improvement vs 47.6% placebo in older patients.
Likely upward bias as traders price improved durability and safety, while noting that Phase IIa endpoint differences were not statistically significant at 12 months.
The article provides specific 12-month responder rates and safety outcomes, but also flags that some individual measures were not statistically significant at that timepoint, limiting conviction until Phase IIb topline.
Market effects
Adds incremental evidence for cell-based/inflammation-targeting approaches in osteoarthritis, potentially improving sentiment toward similar biotech programs.
Limited, as the catalyst is company-specific clinical data for a foreign-listed issuer with a US-listed ticker.
Moderate for global biotech investors tracking durability and safety signals in musculoskeletal indications.
Counterpoint
The lack of statistical significance for individual pain and knee-function measures at 12 months could reduce enthusiasm, making the headline durability less decisive for valuation until Phase IIb confirms efficacy.
Key entities
- companyEnlivex Ltd.
Reports positive 12-month Phase I/IIa Allocetra results in moderate to severe knee osteoarthritis and provides Phase IIb topline timing.
- productAllocetra
Investigational cell-based therapy for knee osteoarthritis, administered as three injections in a single treatment cycle.
- eventACR Convergence 2026
Conference where the 12-month findings will be presented on November 8 in Orlando.